Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 23,62 € (+120,13 %). Medianen er 23,62 € (+120,13 %).
| Køb |
10 |
| Behold |
5 |
| Sælg |
1 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Novocure presents turnaround plan with profitability targets and product launches
At the Morgan Stanley Healthcare Conference, Novocure unveiled a three-stage plan to achieve profitability and for the first time provided financial guidance, targeting adjusted EBITDA break-even by the end of 2025. The company reported 8% volume growth in its glioblastoma business, sees further upside in the US, and identifies Japan as its fourth-largest market. New product launches for pancreatic cancer (Optune Pax, CE mark in Europe) and non-small cell lung cancer are expected to drive growth; Novocure stresses it has roughly $440 million of liquidity to execute the plan. » Mere på de.investing.com
NovoCure: market launches of Optune Pax gain momentum and drive international growth
NovoCure reported at the Wells‑Fargo conference increasing commercial momentum, particularly for Optune Pax in pancreatic cancer with about 600 prescriptions in four months and roughly 285 active patients. The company generated positive cash flow in Q2 2026 for the first time in years and is targeting a clear path to profitability alongside double‑digit revenue growth. Growth drivers also include Optune Gio for glioblastoma and expansion in Japan; risks remain reimbursement, competition from adagrasib, and a recent cybersecurity incident with limited impact. NovoCure is keeping R&D spending around $200 million and plans to hold sales and marketing costs stable, while additional approvals and guideline inclusions should support uptake. » Mere på de.investing.com
NovoCure shows revenue growth but remains cash-flow negative as it expands TTFields devices
NovoCure’s Tumor Treating Fields devices, including Optune Gio and newly FDA-approved Optune Pax, drove revenue growth to about $655–704 million range, but the company posted a net loss (≈$136.2 million in FY2025) and negative free cash flow (−$75.7 million) as it invests in expansion. Debt and a near 0.9x debt-to-equity ratio, reliance on single-source suppliers, and expected negative free cash flow through 2027 pressure financing needs. Valuation looks more attractive than peer Omeros, but NovoCure faces execution and reimbursement risks that could limit near-term shareholder returns. » Mere på finance.yahoo.com
Novocure shares fall after TRIDENT phase‑3 study – primary endpoint missed
The TRIDENT phase‑3 trial by Novocure did not meet its primary endpoint in newly diagnosed glioblastoma: median overall survival 17.7 vs. 17.5 months (hazard ratio 0.953; p=0.519) in 981 patients. The result prevents a potential expansion of Optune Gio use into the earlier radiochemotherapy phase, which had been seen as an important growth driver. Consequently, the stock plunged in pre‑market trading, exacerbated by a risk‑averse market environment after signals from the Fed. » Mere på de.investing.com
NovoCure CEO sells 34,273 shares for about $615,000
Frank Leonard, CEO of NovoCure, reported an open-market sale of 34,273 common shares on June 4, 2026, for roughly $615,000. The sale reduced his direct holdings from 493,793 to 459,520 shares, representing 6.94% of his prior direct stake, and is his largest individual open-market sale to date. No indirect or derivative interests were affected; post-transaction direct holdings were valued at about $8.3 million. » Mere på finance.yahoo.com
Virksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 170,74 mio. | 19,84 % |
| Bruttofortjeneste | 131,43 mio. | 25,93 % |
| Nettoresultat | -9,21 mio. | 70,99 % |
| EBITDA | 1,84 mio. | 108,18 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 1,26 mia. € |
Antal aktier | 116,92 mio. |
Højeste/laveste i 52 uger | 19,49 € - 8,92 € |
| Udbytte | Nej |
Beta | 1,08 |
P/E (PE Ratio) | -11,16 |
PEG (PEG Ratio) | -0,42 |
K/I (PB Ratio) | 3,94 |
P/S (PS Ratio) | 1,91 |
Virksomhedsprofil
NovoCure Limited er et onkologiselskab, der udvikler, fremstiller og kommercialiserer tumor treating fields (TTFields)-udstyr til behandling af solide tumorer i USA, Europa, Mellemøsten, Afrika, Japan og Greater China. Selskabets TTFields-udstyr omfatter Optune til behandling af glioblastom og Optune Lua til behandling af malignt pleuralt mesotheliom. Selskabet har desuden igangværende eller afsluttede kliniske forsøg, der undersøger TTFields ved hjernemetastaser, mavekræft, glioblastom, leverkræft, ikke-småcellet lungekræft, bugspytkirtelkræft og æggestokkræft. NovoCure Limited blev stiftet i 2000 og har hovedkontor i Saint Helier, Jersey.
| Navn | NovoCure |
| CEO | Frank Leonard |
| Hjemsted | Baar,
Israel |
| Websted | |
| Sektor | Sundhed |
| Branche | Sundhedsteknologi |
| Børsnotering | 01.10.2015 |
| Medarbejdere | 1.605 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | NVCR |
Frankfurt | 038.F |
Düsseldorf | 038.DU |
München | 038.MU |